RESUMEN
The spread of chikungunya virus (CHIKV) is reaching pandemic levels, and vaccines and antivirals to control CHIKV infection have yet to be approved. Virus-like particles (VLPs), a self-assembled native multi-subunit protein structure, could potentially be used as an antigen for serological detection and vaccine development. In the current study, we describe the production of novel CHIKV VLPs from mosquitoes using a Baculovirus/Mosquito (BacMos) system in a simple Biosafety Level-2 laboratory. Substantial envelope and capsid protein secretions were detected in culture medium. Co-fractionation of CHIKV E2, E1, and capsid proteins via sucrose gradient ultracentrifugation provided evidence of VLP formation. Transmission electron microscopy and dynamic light scattering analysis revealed the formation of VLPs in the form of spherical particles with a diameter of roughly 40 nm in transduced cells and culture medium. VLP-based IgM capture ELISA in CHIKV patient sera revealed native epitopes on the VLPs. These non-purified VLPs were shown to act as an antigen in CHIKV-specific IgM capture ELISA. The immunization of CHIKV-VLPs alone in mice induced a balance CHIKV-specific IgG2a/IgG1 antibodies and neutralized antibody responses. The study provides support for the hypothesis that mosquito cell-derived CHIKV VLPs could serve as a novel antigen for serological detection and the development of vaccines against CHIKV infection. KEY POINTS: ⢠CHIKV VLPs secreted from BacMos-CHIKV 26S-transduced mosquito cell. ⢠This CHIKV VLPs potentially serve as an alternative capture antigen for MAC-ELISA. ⢠Unadjuvanted CHIK VLPs induce CHIKV-specific IgG and NT responses in mice.
Asunto(s)
Fiebre Chikungunya , Virus Chikungunya , Culicidae , Ratones , Animales , Fiebre Chikungunya/prevención & control , Anticuerpos Antivirales , Inmunoglobulina M , Inmunoglobulina G , Proteínas de la CápsideRESUMEN
BACKGROUND: Yersinia pestis is a contributing agent to the epidemic disease, plague, which killed an estimated 200 million people during historical times. In this study, a rapid, cheap, sensitive, and specific technique, the lateral flow assay (F1 strips), has been successfully developed to detect this pathogen, by using paired monoclonal antibodies (MAbs) against Y. pestis capsule like fraction 1 (F1) protein. Compared with the polyclonal antibody (PAb) based F1 strips, the Mab-based F1 strips have a remarkable increased detection limitation (10 to 100 folds). Furthermore, besides the limitation and specificity evaluation, the application of this F1 strip on simulated clinical samples indicate the LFA can be a good candidate to detect plague. METHODS: Recombinant F1 antigen was expressed and purified from a series of works. The various anti-F1 monoclonal antibodies generated from hybridoma cells were screened with the ELISA technique. To evaluate the feasibility of this Y. pestis F1 test strip, the F1 protein/Y. pestis was spiked into simulated clinical samples such as human serum, mouse bronchoalveolar lavage fluids, and mouse blood to mimic natural infection status. Additionally, this technique was applied to detect the Y. pestis in the environment-captured rats, to evaluate the practical usefulness of the strips. RESULTS: By using this MAb-based-LFA technique, 4 ng/ml of recombinant F1-protein and 103 CFU/ml of Y. pestis could be detected in less than 10 mins, which is at least 10-folds than that of the PAb format. On the other hand, although various Yersinia strains were applied to the strips, only Y. pestis strain showed a positive result; all other Yersinia species did not produce a positive signal, indicating the high efficiency and specificity of the MAb-based F1-strips. CONCLUSION: Based on our findings, we suggest that the MAb-format-LFA will be valuable as a diagnostic tool for the detection of Y. pestis. This report shows that the F1 strip is sufficient to support not only the detection of plague in simulated clinical samples, but also it may be a good candidate to meet the epidemiological surveillance during an outbreak of the biological warfare.
Asunto(s)
Proteínas Bacterianas/sangre , Inmunoensayo/métodos , Yersinia pestis/aislamiento & purificación , Animales , Anticuerpos Monoclonales/inmunología , Proteínas Bacterianas/genética , Proteínas Bacterianas/inmunología , Proteínas Bacterianas/metabolismo , Líquido del Lavado Bronquioalveolar/microbiología , Oro/química , Humanos , Ratones , Peste/diagnóstico , Peste/patología , Ratas , Proteínas Recombinantes/biosíntesis , Proteínas Recombinantes/inmunología , Proteínas Recombinantes/aislamiento & purificación , Sensibilidad y Especificidad , Yersinia pestis/metabolismoRESUMEN
Yersinia pestis, an infectious bacterium that is a causative agent of plague, a disease which has been shown to be one of the most feared in history and which has caused millions of deaths. The capsule-like fraction 1 (F1) antigen expressed by Y. pestis is a known specific marker for the identification of the bacteria; therefore, the detection of F1 is important for Y. pestis recognition. In this study, a rapid, sensitive, and specific technique, the lateral flow assay (LFA), was successfully developed to detect Y. pestis by the recombinant F1 antigen. The assay that utilized an anti-F1 polyclonal antibody (Pab) to identify the bacteria was based on a double-antibody sandwich format on a nitrocellulose membrane. With the LFA method, 50 ng/ml of recombinant F1 protein and 10(5) CFU/mL of Y. pestis could be detected in less than 10 min. This assay also showed no cross-reaction with other Yersinia spp. or with some selected capsule-producing Enterobacteriaceae strains. Furthermore, detection of Y. pestis in simulated samples has been evaluated. The detection sensitivity of Y. pestis in various matrices was 10(5) CFU/mL, which was identical to that in PBS buffer. The results obtained suggest that LFA is an excellent tool for detection of Y. pestis contamination in an environment and hence can be used to monitor plague diseases when they emerge.
Asunto(s)
Proteínas Bacterianas/análisis , Cromatografía de Afinidad/métodos , Pruebas Diagnósticas de Rutina/métodos , Yersinia pestis/aislamiento & purificación , Microbiología Ambiental , Peste/diagnóstico , Sensibilidad y Especificidad , Factores de Tiempo , Yersinia pestis/inmunologíaRESUMEN
Chikungunya fever is a mosquito-transmitted infectious disease that induces rash, myalgia, and persistent incapacitating arthralgia. At present, no vaccines or antiviral therapies specific to Chikungunya virus (CHIKV) infection have been approved, and research is currently restricted to biosafety level 3 containment. CHIKV-like replicon particles (VRPs) are single-cycle infectious particles containing viral structure proteins, as well as a defective genome to provide a safe surrogate for living CHIKV to facilitate the testing of vaccines and antivirals. However, inefficient RNA transfection and the potential emergence of the competent virus through recombination in mammalian cells limit VRP usability. This study describes a transfection-free system for the safe packaging of CHIK VRP with all necessary components via transduction of mosquito cell lines using a single baculovirus vector. We observed the release of substantial quantities of mosquito cell-derived CHIK VRP (mos-CHIK VRP) from baculovirus-transduced mosquito cell lines. The VRPs were shown to recapitulate viral replication and subgenomic dual reporter expression (enhanced green fluorescent protein [eGFP] and luciferase) in infected host cells. Interestingly, the rapid expression kinetics of the VRP-expressing luciferase reporter (6 h) makes it possible to use mos-CHIK VRPs for the rapid quantification of VRP infection. Treatment with antivirals (suramin or 6-azauridine) or neutralizing antibodies (monoclonal antibodies [MAbs] or patient sera) was shown to inhibit mos-CHIK VRP infection in a dose-dependent manner. Ease of manufacture, safety, scalability, and high throughput make mos-CHIK VRPs a highly valuable vehicle for the study of CHIKV biology, the detection of neutralizing (NT) antibody activity, and the screening of antivirals against CHIKV. IMPORTANCE This study proposes a transfection-free system that enables the safe packaging of CHIK VRPs with all necessary components via baculovirus transduction. Those mosquito cell-derived CHIK VRP (mos-CHIK VRPs) were shown to recapitulate viral replication and subgenomic dual reporter (enhanced green fluorescent protein [eGFP] and luciferase) expression in infected host cells. Rapid expression kinetics of the VRP-expressing luciferase reporter (within hours) opens the door to using mos-CHIK VRPs for the rapid quantification of neutralizing antibody and antiviral activity against CHIKV. To the best of our knowledge, this is the first study to report a mosquito cell-derived alphavirus VRP system. Note that this system could also be applied to other arboviruses to model the earliest event in arboviral infection in vertebrates.
RESUMEN
Reverse genetics is an important tool in the elucidation of viral replication and the development of countermeasures; however, these methods are impeded by laborious and inefficient replicon delivery methods. This paper demonstrates the use of a baculovirus to facilitate the efficient delivery of autonomous CHIKV replicons into mosquito and mammalian cells in vitro as well as adult mosquitoes in vivo. The efficacy of this approach was verified via co-localization among an eGFP reporter, nsP1, and dsRNA as well as through the inhibition of an RNA-dependent RNA polymerase (RdRp) null mutation (DDAA) in nsP4, or the treatment of a known antiviral compound (6-azauridine). We also investigated the correlation between CHIKV replicon-launched eGFP expression and the effectiveness of CHIKV replicon variants in inducing IFN-ß expression in human cell lines. This delivery method based on a single vector is applicable to mosquito and mammalian cells in seeking to decipher the mechanisms underlying CHIKV replication, elucidate virus-host interactions, and develop antivirals. This study presents an effective alternative to overcome many of the technological issues related to the study and utilization of autonomous arbovirus replicons.
Asunto(s)
Fiebre Chikungunya/genética , Virus Chikungunya/genética , ARN Polimerasa Dependiente del ARN/genética , Replicación Viral/genética , Aedes/virología , Animales , Antivirales/farmacología , Fiebre Chikungunya/transmisión , Fiebre Chikungunya/virología , Virus Chikungunya/patogenicidad , Chlorocebus aethiops/virología , Culicidae/virología , Humanos , Mosquitos Vectores/genética , Mosquitos Vectores/virología , ARN Viral/genética , Células Vero , Proteínas no Estructurales Virales/genéticaRESUMEN
The spike (S) protein is a leading vaccine candidate against SARS-CoV-2 infection. The S1 domain of S protein, which contains a critical receptor-binding domain (RBD) antigen, potentially induces protective immunoreactivities against SARS-CoV-2. In this study, we presented preclinical evaluations of a novel insect cell-derived SARS-CoV-2 recombinant S1 (rS1) protein as a potent COVID-19 vaccine candidate. The native antigenicity of rS1 was characterized by enzyme-linked immunosorbent assay with a neutralizing monoclonal antibody targeting the RBD antigen. To improve its immunogenicity, rS1-adjuvanted with fucoidan/trimethylchitosan nanoparticles (FUC-TMC NPs) and cytosine-phosphate-guanosine-oligodeoxynucleotides (CpG-ODNs) were investigated using a mouse model. The S1-specific immunoglobulin G (IgG) titers, FluoroSpot assay, pseudovirus- and prototype SARS-CoV-2-based neutralization assays were assessed. The results showed that the rS1/CpG/ FUC-TMC NPs (rS1/CpG/NPs) formulation induced a broad-spectrum IgG response with potent, long-lasting, and cross-protective neutralizing activity against the emerging SARS-CoV-2 variant of concern, along with a Th1-biased cellular response. Thus, the rS1/CpG/NPs formulation presents a promising vaccination approach against COVID-19.
Asunto(s)
Adyuvantes Inmunológicos , Anticuerpos Antivirales/inmunología , Anticuerpos ampliamente neutralizantes/inmunología , Vacunas contra la COVID-19 , Inmunogenicidad Vacunal , Nanopartículas , Oligodesoxirribonucleótidos , SARS-CoV-2/inmunología , Glicoproteína de la Espiga del Coronavirus , Células TH1/inmunología , Adyuvantes Inmunológicos/química , Adyuvantes Inmunológicos/farmacología , Animales , Vacunas contra la COVID-19/química , Vacunas contra la COVID-19/farmacología , Ratones , Ratones Endogámicos BALB C , Nanopartículas/química , Nanopartículas/uso terapéutico , Oligodesoxirribonucleótidos/química , Oligodesoxirribonucleótidos/farmacología , Glicoproteína de la Espiga del Coronavirus/química , Glicoproteína de la Espiga del Coronavirus/farmacologíaRESUMEN
The Japanese encephalitis virus (JEV) is the major cause of an acute encephalitis syndrome in many Asian countries, despite the fact that an effective vaccine has been developed. Virus-like particles (VLPs) are self-assembled multi-subunit protein structures which possess specific epitope antigenicities related to corresponding native viruses. These properties mean that VLPs are considered safe antigens that can be used in clinical applications. In this study, we developed a novel baculovirus/mosquito (BacMos) expression system which potentially enables the scalable production of JEV genotype III (GIII) VLPs (which are secreted from mosquito cells). The mosquito-cell-derived JEV VLPs comprised 30-nm spherical particles as well as precursor membrane protein (prM) and envelope (E) proteins with densities that ranged from 30% to 55% across a sucrose gradient. We used IgM antibody-capture enzyme-linked immunosorbent assays to assess the resemblance between VLPs and authentic virions and thereby characterized the epitope specific antigenicity of VLPs. VLP immunization was found to elicit a specific immune response toward a balanced IgG2a/IgG1 ratio. This response effectively neutralized both JEV GI and GIII and elicited a mixed Th1/Th2 response in mice. This study supports the development of mosquito cell-derived JEV VLPs to serve as candidate vaccines against JEV.
Asunto(s)
Virus de la Encefalitis Japonesa (Especie)/inmunología , Virus de la Encefalitis Japonesa (Especie)/ultraestructura , Encefalitis Japonesa/inmunología , Encefalitis Japonesa/virología , Inmunidad Celular , Inmunidad Humoral , Vacunas de Partículas Similares a Virus/inmunología , Animales , Anticuerpos Neutralizantes/inmunología , Anticuerpos Antivirales/inmunología , Línea Celular , Culicidae/virología , Citocinas/metabolismo , Modelos Animales de Enfermedad , Ensayo de Inmunoadsorción Enzimática , Epítopos/inmunología , Técnica del Anticuerpo Fluorescente , Ratones , Pruebas de Neutralización , ViriónRESUMEN
A rapid immunochromatographic assay was developed to detect botulinum neurotoxin type B (BoNT/B). The assay was based on the sandwich format using polyclonal antibody (Pab). The thiophilic gel purified anti-BoNT/B Pab was immobilized to a defined detection zone on a porous nitrocellulose membrane and conjugated to colloidal gold particles that served as a detection reagent. The BoNT/B-containing sample was added to the membrane and allowed to react with Pab-coated particles. The mixture was then passed along the porous membrane by capillary action past the Pab in the detection zone, which will bind the particles that had BoNT/B bound to their surface, giving a red colour within this detection zone with an intensity proportional to BoNT/B concentration. In the absence of BoNT/B, no immunogold was bound to the solid-phase antibody. With this method, 50 ng/ml of BoNT/B was detected in less than 10 min. The assay sensitivity can be increased by silver enhancement to 50 pg/ml. The developed BoNT/B assay also showed no cross reaction to type A neurotoxin (BoNT/A) and type E neurotoxin (BoNT/E).
Asunto(s)
Toxinas Botulínicas/análisis , Cromatografía Liquida/métodos , Coloides/química , Oro/química , Toxinas Botulínicas Tipo A , Reacciones Cruzadas , Sensibilidad y EspecificidadRESUMEN
Three sensitive and specific assays, the lateral flow assay (LFA), polymerase chain reaction assay (PCR) and reversed passive latex agglutination assay (RPLA), were selected for detection of staphylococcal enterotoxin B (SEB) from 77 clinical Staphylococcus aureus strains isolated from humans. Analytical results revealed that the LFA has almost the same detection sensitivity as that of PCR and RPLA. The concordances between the 3 assays were as follows: LFA-PCR, 92.2%; LFA-RPLA, 94.8%; and PCR-RPLA, 97.4%. For further evaluation, the LFA was used for the detection of SEB in different food matrices. The assay was able to successfully identify SEB in a wide variety of food samples at levels as low as 10 ng/mL in less than 10 min. This study proved that the LFA is an excellent tool for detection of SEB both in isolated clinical S. aureus strains and in food specimens and may prove particularly important as an early warning tool to prevent food poisoning in consumers.
Asunto(s)
Enterotoxinas/análisis , Contaminación de Alimentos/análisis , Pruebas de Fijación de Látex/métodos , Reacción en Cadena de la Polimerasa/métodos , Infecciones Estafilocócicas/microbiología , Staphylococcus aureus/aislamiento & purificación , Enterotoxinas/genética , Microbiología de Alimentos , Humanos , Infecciones Estafilocócicas/diagnóstico , Staphylococcus aureus/genéticaRESUMEN
Clostridial botulinum neurotoxin (BoNT) is one of the most toxic proteins causing the food borne disease, botulism. In previous studies, recombinant BoNT production by Escherichia coli and yeast Pichia pastoris has been hampered by high AT content and codon bias in the gene encoding BoNT and required a synthetic gene to resolve this intrinsic bottleneck. This paper reports the simultaneous expression of the C-terminal heavy chain domain of BoNT (rBoNT/A-HC-6h) and enhanced green fluorescent protein (EGFP) using a bi-cistronic baculovirus-insect cell expression system. The expression of EGFP facilitated the monitoring of viral infection, virus titer determination, and isolation of the recombinant virus. Protein fusion with hexa-His-tag and one-step immobilized metal-ion affinity chromatography (IMAC) purification produced a homogenous, stable, and immunologically active 55-kDa rBoNT/A-HC-6h (about 3mg/L) with >90% purity. Furthermore, measured levels of serum titers were 8-folds for mice vaccinated with the purified rBoNT/A-HC-6h (2µg) than for mice administered with botulinum toxoid after initial immunization. Challenge experiment with botulinum A toxin demonstrated the immunoprotective activity of purified rBoNT/A-HC-6h providing the mice full protection against 10(2) LD50 botulinum A toxin with a dose as low as 0.2µg. This study provided supportive evidence for the use of a bi-cistronic baculovirus-Sf21 insect cell expression system in the facile expression of an immunogenically active rBoNT/A-HC.
Asunto(s)
Vacunas Bacterianas/inmunología , Toxinas Botulínicas Tipo A/genética , Toxinas Botulínicas Tipo A/inmunología , Botulismo/inmunología , Animales , Anticuerpos Antibacterianos , Baculoviridae/genética , Botulismo/prevención & control , Línea Celular , Proteínas Fluorescentes Verdes/genética , Ratones , Ratones Endogámicos BALB C , Proteínas Recombinantes/genética , Proteínas Recombinantes/inmunología , Células Sf9 , SpodopteraRESUMEN
A sensitive and specific ELISA was developed to detect BoNT/A in biological fluids. The assay is based on the sandwich format using monoclonal antibodies (MAb) of two distinct specificities. An affinity-purified anti-BoNT/A heavy chain MAb (150-3) is utilized to adsorb BoNT/A from solution; the second anti-BoNT/A heavy chain MAb (44-1A) conjugated with peroxidase is then used to form a sandwich. Peroxidase allows color development and measurement of optical density at 450 nm. Standard curves were linear over the range of 2.5 to 100 ng/mL BoNT/A. The limit of detection was below 5 ng/mL in assay buffer, as well as in a 1:10 dilution of urine or 1:50 dilution of human serum spiked with BoNT/A. The developed BoNT/A assay also showed no cross-reaction to type B neurotoxin (BoNT/B) and type E neurotoxin (BoNT/E).
Asunto(s)
Anticuerpos Monoclonales/aislamiento & purificación , Toxinas Botulínicas Tipo A/análisis , Animales , Anticuerpos Monoclonales/química , Toxinas Botulínicas Tipo A/inmunología , Reacciones Cruzadas , Ensayo de Inmunoadsorción Enzimática , Humanos , Hibridomas/inmunología , Cadenas Pesadas de Inmunoglobulina/química , Cadenas Pesadas de Inmunoglobulina/aislamiento & purificación , Mediciones Luminiscentes , Ratones , Ratones Endogámicos BALB C , Peroxidasa/químicaRESUMEN
A rapid lateral flow assay was developed to detect botulinum neurotoxin type A (BoNT/A). The assay was based on the sandwich format using monoclonal antibodies (MAbs) of two distinct specificities. One anti-BoNT/A heavy chain MAb (150-3) was immobilized to a defined detection zone on a porous nitrocellulose membrane, while the other anti-BoNT/A heavy chain MAb (44.1) was conjugated to colloidal gold particles, which served as a detection reagent. The BoNT/A-containing sample was added to the strip and allowed to react with MAb (44.1)-coated particles. The mixture was then passed along the porous membrane by capillary action past the MAb (150-3) in the detection zone, which binds the particles that had BoNT/A bound to their surface, giving a red color within this detection zone with intensity proportional to BoNT/A concentration. In the absence of BoNT/A, no immunogold was bound to the solid-phase antibody. With this method, 50 ng/mL of BoNT/A were detected in less than 10 min. The assay sensitivity can be increased by silver enhancement to 1 ng/mL. The developed BoNT/A assay also showed no cross-reaction to type B neurotoxin (BoNT/B) and type E neurotoxin (BoNT/E).
Asunto(s)
Anticuerpos Monoclonales/química , Toxinas Botulínicas Tipo A/análisis , Reacciones Antígeno-Anticuerpo , Oro Coloide/química , Inmunoensayo/métodosRESUMEN
A sensitive and specific enzyme-linked immunoadsorbent assay (ELISA) was developed to detect ricin in biological fluids. The assay is based on the sandwich format using monoclonal antibodies (MAbs) of two distinct specificities. An affinity-purified anti-ricin B chain MAb (1G7) is utilized to adsorb ricin from solution and the second anti-ricin A chain MAb (5E11) conjugated with peroxidase is then used to form a sandwich, and peroxidase allows color development and measurement of optical density at 450 nm. Standard curves were linear over the range of 2.5-100 ng/mL ricin. The limit of detection was below 5 ng/mL in assay buffer as well as in a 1:10 dilution of urine or 1:50 dilution of human serum spiked with ricin.